Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191393 | 0.84 | POLB (0.74) | ALDH1A1CYP2D6POLBKDM4ENAMPT | |
| SCHEMBL4071582 | 0.84 | ALDH1A1 (0.72) | ALDH1A1CYP2D6POLBKDM4EGAA | |
| SCHEMBL4062604 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CYP2D6POLBKDM4EGAA | |
| SCHEMBL3182368 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBKDM4ENAMPT | |
| SCHEMBL3196506 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBKDM4EGAA | |
| SCHEMBL3203109 | 0.81 | POLB (0.72) | ALDH1A1CYP2D6POLBLMNASMN1; SMN2 | |
| SCHEMBL3205826 | 0.80 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBKDM4ENAMPT | |
| SCHEMBL12169346 | 0.79 | L3MBTL1 (0.64) | ALDH1A1POLBKDM4EGAALMNA | |
| SCHEMBL12169395 | 0.78 | KDM2B (0.65) | ALDH1A1POLBKDM4EKDM2BGAA | |
| SCHEMBL2839179 | 0.78 | RAB9A (0.63) | ALDH1A1POLBKDM4EGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | claimed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | claimed |
| US-7683067-B2 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | ASTRAZENECA AB (SE) | 2010-03-23 | — | — | US | disclosed |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | GSK3B, GSK3A, GSKIP | ALDH1A1 2460/4885CYP2D6 1098/4885POLB 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.